FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma By Ogkologos - February 25, 2026 355 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant MOST POPULAR How I Coped With My Own Cancer Diagnoses As an Oncologist October 13, 2022 Why do non-smokers face delays in getting a lung cancer diagnosis? November 25, 2022 Miss New Jersey Collegiate USA Uses Her Prestigious Position to Shed... March 31, 2021 A Rare Childbirth Complication Wiped This Woman’s Memory Of Giving Birth... December 4, 2019 Load more HOT NEWS Weak Immunogenicity in Patients with Cancer After First Dose of mRNA-based... Clinical and Biological Activity of Patritumab Deruxtecan in Patients with HR-positive,... Identical Twins Find Strength in Shared Breast Cancer Battle After Being... Percentage of Cancer Patients Who Are Eligible for and Respond to...
